Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 8/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21660930 | 1.00 | TLR8 (0.44) | TLR8TLR9TLR7ALDH1A1GAA | |
| SCHEMBL21661161 | 0.92 | TLR9 (0.45) | TLR8TLR9TLR7ALDH1A1GAA | |
| SCHEMBL21661571 | 0.92 | TLR9 (0.45) | TLR8TLR9TLR7ALDH1A1GAA | |
| SCHEMBL23855159 | 0.92 | TLR9 (0.45) | TLR8TLR9TLR7ALDH1A1GAA | |
| SCHEMBL21661575 | 0.91 | TLR9 (0.46) | TLR8TLR9TLR7ALDH1A1GAA | |
| SCHEMBL21661573 | 0.91 | TLR9 (0.46) | TLR8TLR9TLR7ALDH1A1GAA | |
| SCHEMBL21661162 | 0.89 | TLR8 (0.45) | TLR8TLR9TLR7ALDH1A1GAA | |
| SCHEMBL21661160 | 0.87 | TLR8 (0.51) | TLR8TLR9TLR7ALDH1A1GAA | |
| SCHEMBL21661159 | 0.87 | TLR8 (0.51) | TLR8TLR9TLR7ALDH1A1GAA | |
| SCHEMBL21661163 | 0.87 | TLR9 (0.49) | TLR8TLR9TLR7ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-09-30 | — | — | US | disclosed |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-09-30 | — | — | US | disclosed |
| WO-2020025517-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | TLR8 2/4885TLR9 3/4885TLR7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.